These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 23838604)

  • 1. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema.
    Pare G; Kubo M; Byrd JB; McCarty CA; Woodard-Grice A; Teo KK; Anand SS; Zuvich RL; Bradford Y; Ross S; Nakamura Y; Ritchie M; Brown NJ
    Pharmacogenet Genomics; 2013 Sep; 23(9):470-8. PubMed ID: 23838604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic markers for antihypertensive drug-related adverse reactions.
    Cerda A; Hirata RD; Hirata MH
    Pharmacogenomics; 2013 Nov; 14(15):1819-20. PubMed ID: 24386648
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
    Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
    Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telmisartan, ramipril, or both in patients at high risk for vascular events.
    ; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
    N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
    Yu LT; Zhu J; Tan HQ; Wang GG; Teo KK; Liu LS
    Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].
    Düsing R; Nitschmann S
    Internist (Berl); 2008 Sep; 49(9):1137-40. PubMed ID: 18665340
    [No Abstract]   [Full Text] [Related]  

  • 7. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
    Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
    Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pollen count and presentation of angiotensin-converting enzyme inhibitor-associated angioedema.
    Straka B; Nian H; Sloan C; Byrd JB; Woodard-Grice A; Yu C; Stone E; Steven G; Hartert T; Teo KK; Pare G; McCarty CA; Brown NJ
    J Allergy Clin Immunol Pract; 2013; 1(5):468-73.e1-4. PubMed ID: 24565618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme.
    Anderson C
    J Int Med Res; 2005; 33 Suppl 1():50A-57A. PubMed ID: 16222900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
    Unger T
    Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics.
    Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL
    Clin Res Cardiol; 2009 Jul; 98(7):421-33. PubMed ID: 19347385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema.
    Woodard-Grice AV; Lucisano AC; Byrd JB; Stone ER; Simmons WH; Brown NJ
    Pharmacogenet Genomics; 2010 Sep; 20(9):532-6. PubMed ID: 20625347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
    Böhm M; Baumhäkel M; Teo K; Sleight P; Probstfield J; Gao P; Mann JF; Diaz R; Dagenais GR; Jennings GL; Liu L; Jansky P; Yusuf S;
    Circulation; 2010 Mar; 121(12):1439-46. PubMed ID: 20231536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
    Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
    Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk.
    Liebson PR; Amsterdam EA
    Prev Cardiol; 2009; 12(1):43-50. PubMed ID: 19301691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema?
    Howes LG; Tran D
    Drug Saf; 2002; 25(2):73-6. PubMed ID: 11888349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.